Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics
08 sept. 2020 08h00 HE
|
Menlo Therapeutics Inc.
Will commence trading under new Nasdaq Ticker “VYNE”, September 8, 2020 Company to ring Nasdaq Closing Bell at 4pm ET today BRIDGEWATER, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics...
Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics
02 sept. 2020 08h00 HE
|
Menlo Therapeutics Inc.
Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8 BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo...
Menlo Reports Second Quarter 2020 Financial Results and Provides Business Update
06 août 2020 07h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6
28 juil. 2020 08h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
Menlo Therapeutics Announces Pricing of Offering of Common Stock
05 juin 2020 07h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary...
Menlo Therapeutics Announces Proposed Offering of Common Stock
04 juin 2020 16h01 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary...
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris
02 juin 2020 08h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea
29 mai 2020 11h38 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., May 29, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
Menlo Therapeutics Announces Covered Status for AMZEEQ® (minocycline) topical foam, 4%, on Additional Commercial Formulary
27 mai 2020 08h00 HE
|
Menlo Therapeutics Inc.
Coverage Effective Immediately on One of the Largest Payor Networks in the U.S. AMZEEQ® is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne ...
Menlo Therapeutics to Present at the Jefferies Virtual Healthcare Conference
26 mai 2020 08h00 HE
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...